Callan JMB Expands Oversight Role in Attune Biotech’s Long COVID Trial
Event summary
- Callan JMB will oversee manufacturing and quality control for Attune Biotech’s Phase 2b/3 clinical trial of lodonal™ for Long COVID.
- The trial (IND 181314) follows a January 2026 strategic teaming agreement between the two companies.
- Lodonal™ (JKB-122) is a first-in-class TLR4 antagonist targeting immune restoration in five parallel clinical programs.
- Approximately 20 million Americans live with Long COVID, with no FDA-approved therapies currently available.
The big picture
Callan JMB’s expanded role underscores the growing intersection of logistics and biopharmaceutical development, particularly for underserved conditions like Long COVID. With 20 million potential patients and no FDA-approved treatments, the trial’s success could validate Callan JMB’s governance model for high-compliance clinical supply chains. The partnership also highlights the strategic value of third-party oversight in accelerating drug development timelines.
What we're watching
- Regulatory Momentum
- Whether the FDA’s acceptance of the IND application accelerates lodonal™’s path to market.
- Operational Scalability
- How Callan JMB’s oversight framework handles surge manufacturing demands for Attune’s pipeline.
- Market Differentiation
- The pace at which lodonal™ can establish clinical efficacy in Long COVID amid competitive therapies.
Related topics